Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$71.8 million.

  • Bicycle Therapeutics' Free Cash Flow fell 7842.65% to -$71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$241.9 million, marking a year-over-year decrease of 1883.47%. This contributed to the annual value of -$166.0 million for FY2024, which is 16111.84% down from last year.
  • Per Bicycle Therapeutics' latest filing, its Free Cash Flow stood at -$71.8 million for Q3 2025, which was down 7842.65% from -$73.3 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Free Cash Flow registered a high of $33.8 million during Q2 2023, and its lowest value of -$87.0 million during Q1 2025.
  • Its 5-year average for Free Cash Flow is -$30.7 million, with a median of -$31.8 million in 2022.
  • In the last 5 years, Bicycle Therapeutics' Free Cash Flow surged by 31377.98% in 2021 and then plummeted by 253700.07% in 2024.
  • Bicycle Therapeutics' Free Cash Flow (Quarter) stood at -$11.5 million in 2021, then plummeted by 176.1% to -$31.8 million in 2022, then tumbled by 49.07% to -$47.3 million in 2023, then surged by 79.37% to -$9.8 million in 2024, then tumbled by 635.84% to -$71.8 million in 2025.
  • Its Free Cash Flow was -$71.8 million in Q3 2025, compared to -$73.3 million in Q2 2025 and -$87.0 million in Q1 2025.